Oramed Pharma (ORMP)

Apr 28, 2025, 9:00 AM EDT - 5 weeks ago

Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical

DRTS

Apr 28, 2025, 9:00 AM EDT - 5 weeks ago

Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals

DRTS

Mar 4, 2025, 9:00 AM EST - 3 months ago

Oramed Pharmaceuticals Issues Letter to Shareholders

Feb 11, 2025, 9:15 AM EST - 4 months ago

Oramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral Insulin

Oct 7, 2024, 10:00 AM EDT - 8 months ago

Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt

SCLX

Jun 26, 2024, 9:05 AM EDT - 1 year ago

Oramed Letter to Shareholders

Jun 26, 2024, 9:00 AM EDT - 1 year ago

Oramed Pharmaceuticals Inc. Announces the Buy-Back of its Common Stock

Sep 21, 2023, 6:11 PM EDT - 1 year ago

Oramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding Company

Aug 2, 2023, 7:45 AM EDT - 2 years ago

Oramed Signs Term Sheet with HTIT to Create a Joint Venture to Advance Oral Drug Delivery Technology Globally

Jun 20, 2023, 7:55 AM EDT - 2 years ago

Oramed to Present at the 83rd American Diabetes Association Conference

May 18, 2023, 7:55 AM EDT - 2 years ago

Oramed to Present at Novel Therapies for Type 2 Diabetes & Obesity Summit

May 15, 2023, 9:05 AM EDT - 2 years ago

Oramed Announces that its Chinese Partner, HTIT, has Successfully Completed a Phase 3 Oral Insulin Clinical Trial and Submitted a Marketing Authorization Application in China

Feb 9, 2023, 7:55 AM EST - 2 years ago

Oramed Pharmaceuticals Issues Shareholder Update

Jan 12, 2023, 8:02 AM EST - 2 years ago

Oramed's oral insulin pill fails; stock is down 72%

Jan 11, 2023, 8:00 PM EST - 2 years ago

Oramed Announces Top-line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 Diabetes

Jan 4, 2023, 7:55 AM EST - 2 years ago

Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes

Dec 7, 2022, 3:49 AM EST - 2 years ago

Oramed: NASH Biotech Play With Added Bonus

Nov 29, 2022, 8:40 AM EST - 2 years ago

Oramed Announces Publication of Oral Insulin Study in Peer-Reviewed Journal: Diabetes, Obesity, and Metabolism

Nov 18, 2022, 4:11 AM EST - 2 years ago

MEDICOX Signs Contract with ORAMED to Distribute Oral Insulin in South Korea

Nov 14, 2022, 7:55 AM EST - 2 years ago

Oramed Signs Definitive Deal with Medicox to Commercialize Oral Insulin in South Korea

Nov 10, 2022, 4:30 PM EST - 2 years ago

Oramed Reports Third Quarter 2022 Financial Results

Nov 9, 2022, 8:40 AM EST - 2 years ago

Oramed to Host Webinar Highlighting Detailed Safety and Efficacy Data from Its Positive Phase 2 Clinical Trial of ORMD-0801 for NASH

Oct 7, 2022, 8:40 AM EDT - 2 years ago

Oramed Subsidiary Oravax Reports Positive Preliminary Phase 1 Data for its Oral Covid-19 Vaccine

Sep 21, 2022, 5:52 AM EDT - 2 years ago

Oramed: Oral Insulin For Type 2 Diabetes May Become A Reality

Sep 13, 2022, 8:40 AM EDT - 2 years ago

Oramed Reports Positive Top-Line Results from Phase 2 NASH Trial with its ORMD-0801, Oral Insulin Candidate

Sep 6, 2022, 7:55 AM EDT - 2 years ago

Oramed to Present at H.C. Wainwright 24th Annual Global Investment Conference

Jul 26, 2022, 7:55 AM EDT - 3 years ago

Oramed Reaches 50% Enrollment in its Second Phase 3 Oral Insulin Trial

Jul 11, 2022, 7:55 AM EDT - 3 years ago

Oramed to Present at the Upcoming Canaccord Genuity Annual Growth Conference

Jun 1, 2022, 7:55 AM EDT - 3 years ago

Oramed Appoints Dr. Anne Peters to its Scientific Advisory Board

May 18, 2022, 7:55 AM EDT - 3 years ago

Oramed to Present at H.C. Wainwright Global Investment Conference

May 3, 2022, 8:10 AM EDT - 3 years ago

Oramed Completes Patient Enrollment in Pivotal Phase 3 Oral Insulin Study ORA-D-013-1

Apr 14, 2022, 4:02 PM EDT - 3 years ago

Oramed And Oral Insulin: Can This Small Company Really Do It?

Apr 4, 2022, 8:25 AM EDT - 3 years ago

Oramed Appoints Yadin Rozov to its Board of Directors

Mar 29, 2022, 8:25 AM EDT - 3 years ago

Oramed's Diabetes Market Survey Shows Strong Interest for ORMD-0801 Oral Insulin Candidate Among Physicians

Mar 22, 2022, 8:25 AM EDT - 3 years ago

Oramed to Host Key Opinion Leader Webinar on Need for Oral Insulin in Type 2 Diabetes

Mar 10, 2022, 8:25 AM EST - 3 years ago

Oramed to Present at Barclays Global Healthcare Conference

Jan 12, 2022, 8:45 AM EST - 3 years ago

Oramed Issues Annual Message to Shareholders

Jan 5, 2022, 7:30 AM EST - 3 years ago

Oramed Granted Key European Patent for Platform Technology in Oral Delivery of Proteins

Dec 29, 2021, 9:15 AM EST - 3 years ago

MyMD Pharmaceuticals Investment Company Oravax Medical Signs Cooperation and Purchase Agreement for Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccine to be Commercialized in Southeast Asia

Dec 29, 2021, 6:14 AM EST - 3 years ago

Oramed's Oravax sub signs pre-purchase agreement for 10 million oral COVID-19 vaccines with Tan Thanh

Dec 29, 2021, 6:00 AM EST - 3 years ago

Oramed Subsidiary Oravax Medical Signs Cooperation and Purchase Agreement for an Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccines with Tan Thanh Holdings to Commercialize in Southeast Asia

Dec 14, 2021, 8:00 AM EST - 3 years ago

Oramed Subsidiary Oravax Announces First Participant Enrolled in Phase 1 Oral COVID-19 Vaccine Trial in South Africa

Dec 8, 2021, 7:30 AM EST - 3 years ago

Oramed Pharmaceuticals Appoints Chief Legal Officer

Nov 24, 2021, 8:40 AM EST - 3 years ago

Oramed to Join MSCI USA Small Cap Index

Nov 23, 2021, 8:25 AM EST - 3 years ago

Oramed Reaches 75% Enrollment in Phase 3 Oral Insulin Study

Nov 18, 2021, 9:15 AM EST - 3 years ago

MyMD Pharmaceuticals Investment Company Oravax Medical and Genomma Lab Announce Joint Venture to Develop and Commercialize Oral COVID-19 Vaccine in Mexico and Drive Business Development in Latin America

Nov 18, 2021, 7:40 AM EST - 3 years ago

Oramed Subsidiary Oravax Medical and Genomma Lab Internacional Announce Joint Venture to Develop and Commercialize Oral COVID-19 Vaccine in Mexico and Drive Business Development in Latin America

Nov 11, 2021, 9:25 AM EST - 3 years ago

Oramed to Present at H.C. Wainwright 7th Annual Israel Conference

Nov 8, 2021, 8:10 AM EST - 3 years ago

Oramed Announces Closing of $50 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules

Nov 3, 2021, 11:59 AM EDT - 3 years ago

Oramed Announces $50 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules